hymecromone and Syndrome

hymecromone has been researched along with Syndrome* in 1 studies

Other Studies

1 other study(ies) available for hymecromone and Syndrome

Article	Year
[Clinical observations on the therapeutic activity of the preparation mendiaxon in diseases of the biliary tract]. Vutreshni bolesti, 1982, Volume: 21, Issue:3 The immediate effect of 400 mg mendiaxon was studied in 8 patients with various hepatobiliary diseases. The drug was administered via a duodenal tube in a duodenal drainage tubing according to a minute schedule during the phase of pure bile C secretion. An increased volume was found in all cases. The maximum choleresis exceeds the basal one from 3 to 8 times. The rate of bile flow, in the majority of the patients, was between 2 and 3.3. ml/min. The treatment was carried out on 25 patients in the course of 10 days with a daily dose of 1200 mg (400 mg three times). A good pain-killing effect was obtained. Adverse effects and allergic reactions were not observed. The results from our studies provided grounds to recommend mendiaxon use in the clinical practice. Topics: Adult; Aged; Biliary Tract Diseases; Cholagogues and Choleretics; Cholecystectomy; Cholecystitis; Cholelithiasis; Female; Humans; Hymecromone; Liver Cirrhosis; Male; Middle Aged; Parasympatholytics; Postoperative Complications; Syndrome; Umbelliferones	1982

Article

Year

[Clinical observations on the therapeutic activity of the preparation mendiaxon in diseases of the biliary tract].

Vutreshni bolesti, 1982, Volume: 21, Issue:3

The immediate effect of 400 mg mendiaxon was studied in 8 patients with various hepatobiliary diseases. The drug was administered via a duodenal tube in a duodenal drainage tubing according to a minute schedule during the phase of pure bile C secretion. An increased volume was found in all cases. The maximum choleresis exceeds the basal one from 3 to 8 times. The rate of bile flow, in the majority of the patients, was between 2 and 3.3. ml/min. The treatment was carried out on 25 patients in the course of 10 days with a daily dose of 1200 mg (400 mg three times). A good pain-killing effect was obtained. Adverse effects and allergic reactions were not observed. The results from our studies provided grounds to recommend mendiaxon use in the clinical practice.

Topics: Adult; Aged; Biliary Tract Diseases; Cholagogues and Choleretics; Cholecystectomy; Cholecystitis; Cholelithiasis; Female; Humans; Hymecromone; Liver Cirrhosis; Male; Middle Aged; Parasympatholytics; Postoperative Complications; Syndrome; Umbelliferones

1982